tiprankstipranks
The Fly

Dynavax sees FY25 adjusted EBITDA ‘at least $75M’ vs. $51.9M in FY24

Dynavax sees FY25 adjusted EBITDA ‘at least $75M’ vs. $51.9M in FY24

FY25 HEPLISAV-B net product revenue is expected in the range of $305M to $325M

Discover the Best Stocks and Maximize Your Portfolio:

Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>

Looking for investment ideas? Subscribe to our Smart Investor newsletter for weekly expert stock picks!
Get real-time notifications on news & analysis, curated for your stock watchlist. Download the TipRanks app today! Get the App
1